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ethanolamide; PGE2, prostaglandin E2; PGE2-EA, prostaglandin E2 ethanolamide; PMSF, 
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 Abstract 
Free arachidonic acid is functionally interlinked with different lipid signaling networks 
including those involving prostanoid pathways, the endocannabinoid system, N-
acylethanolamines, as well as steroids. A sensitive and specific LC-MS/MS method for 
the quantification of arachidonic acid, prostaglandin E2, thromboxane B2, anandamide, 
2-arachidonoylglycerol, noladin ether, lineoyl ethanolamide, oleoyl ethanolamide, 
palmitoyl ethanolamide, steroyl ethanolamide, aldosterone, cortisol, 
dehydroepiandrosterone, progesterone, and testosterone in human plasma was 
developed and validated. Analytes were extracted using acetonitrile precipitation 
followed by solid phase extraction. Separations were performed by UFLC using a C18 
column and analyzed on a triple quadrupole MS with electron spray ionization. Analytes 
were run first in negative mode and, subsequently, in positive mode in two independent 
LC-MS/MS runs. For each analyte, two MRM transitions were collected in order to 
confirm identity. All analytes showed good linearity over the investigated concentration 
range (r > 0.98). Validated LLOQs ranged from 0.1 to 190 ng/mL and LODs ranged from 
0.04 to 12.3 ng/mL. Our data show that this LC-MS/MS method is suitable for the 
quantification of a diverse set of bioactive lipids in plasma from human donors (n=32). 
The determined plasma levels are in agreement with the literature, thus providing a 
versatile method to explore pathophysiological processes in which changes of these 
lipids are implicated.  
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 1. Introduction 
Arachidonic acid (AA) is not only an abundant component of cell membranes 
(incorporated into phospholipids), but also is the precursor of prostanoids and all 
endocannabinoids (ECs). Thus, AA is of primary importance in neuro- and 
immunomodulation, energy metabolism, as well as the cardiovascular system [1–3]. 
The pool of free AA, which may vary in different tissues and between individuals, is 
known to be regulated by phospholipase A2 (PLA2) and 2-arachidonoyl glycerol (2-AG) 
hydrolysis. Recently, the levels of 2-AG and AA were shown to inversely correlate with 
the free AA generated upon hydrolysis of 2-AG which was shown to act as precursor for 
eicosanoid biosynthesis [4]. Prostanoids are a family of lipid mediators that play key 
roles in both inflammatory and neuropsychiatric processes. They are produced upon the 
enzymatic oxygenation of AA by cyclooxygenase-2 (COX-2) resulting in e.g. the 
production of prostaglandin E2 (PGE2) and thromboxane B2 (THB B2)  [5]. Attention has 
recently been paid to the fact that like AA, ECs containing an arachidonoyl moiety are 
good substrates of COX-2, leading to the formation of similar prostanoid derivatives 
(e.g., prostaglandin E2 ethanolamide (PGE2EA)) [6].  
The endocannabinoid system is involved in different physiological and 
pathophysiological processes that occur mainly in the central nervous system (CNS) 
and immune system, but  also exerts regulatory effects on metabolic processes and 
vascular tone [7]. ECs are produced “on demand” in the body from precursor 
phospholipids containing arachidonyl moieties derived from arachidonic acid including 
N-acylphosphatidylethanolamine (NAPE) and diacylglycerol (DAG) [8,9]. These 
bioactive lipids are not stored in vesicles, but are transported across the plasma 
membrane by as yet poorly understood mechanisms [10]. The distribution of ECs 
between tissues and plasma is not equal and a correlation between brain and plasma 
levels cannot be drawn, unless experimentally shown. By definition, ECs interact with 
both central (CB1) and peripheral (CB2) G protein-coupled cannabinoid receptors and 
act as partial or full agonists [9]. The most important and best studied ECs are 
anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), which can be found in 
numerous tissues [9,11]. In addition to the classical ECs, virodhamine (VIR), noladin 
ether (NE) and N-arachidonoyl dopamine (NADA) have been proposed to act as ECs 
 [12]. However, only limited information is available about the quantifiable amounts of 
these minor ECs in plasma and tissues. Another class of related compounds are amino 
acid conjugates (e.g., N-arachidonoyl-gamma-aminobutyric acid (A-GABA), N-
arachidonoyl-glycine (A-GLY) and N-arachidonoyl-serine (A-SER)), which have also 
been proposed to exert physiological effects [13,14]. Furthermore, N-acylethanolamines 
other than AEA, which exhibit distinct saturated or unsaturated fatty acids and show no 
(or little) direct effect on CB receptors (i.e., linoleoyl ethanolamide (LEA), palmitoyl 
ethanolamide (PEA), oleoyl ethanolamide (OEA), stearoyl ethanolamide (SEA)), have 
been shown to act as ECs entourage molecules, possibly acting in concert with ECs 
[15–18].  Yet another important class of signaling lipids involves the steroids, which 
appear to functionally interlink the different AA lipid signaling networks, including the 
endocannabinoid system [19,20]. Steroids (glucocorticoids and mineralocorticoids) are 
involved in numerous physiological processes, including immunomodulation [21]. They 
are generated from cholesterol in the adrenal glands or the gonads, but some can also 
be formed in the CNS (neurosteroids) [22,23].  
 LC-MS/MS is a useful method for the quantitative analysis of lipophilic and apolar 
metabolites because it allows short analysis time, complete automation, minimal sample 
preparation (no derivatization), and it is applicable to analytes with a broad range of 
molecular masses and polarities. It has been widely used for the analysis of ECs and 
similar lipids [24–28]. However, it has only recently been used for the analysis of 
steroids [29–31].  
To our knowledge, this is the first time that an LC-MS/MS method has been 
developed to analyze a combination of different biologically important lipids, including 
diverse arachidonic acid metabolites, N-acylethanolamines and steroids simultaneously 
in human plasma. The development of a sensitive analytical method to measure a wide 
range of lipids at physiological concentrations is required to evaluate the role of these 
metabolites and their possible cross talk in different diseases. In this study, we report a 
fully validated analytical LC-MS/MS method that first allows the simultaneous 
measurement of AA, PGE2 and THB B2 in the negative mode and, subsequently, AEA, 
2-AG, aldosterone (ALDO), cortisol (COR), dehydroepiandrosterone (DHEA), LEA, NE, 
 OEA, PEA, progesterone (PROG), SEA and testosterone (TEST) in the positive mode 
in two LC-MS/MS runs.  
 
2. Materials and methods 
 
2.1. Materials 
Analytical and internal standards were purchased from Cayman Chemical, Tallinn, 
Estonia  (arachidonic acid (AA or 5Z,8Z,11Z,14Z-eicosatetraenoic acid); AA-d8 
(5Z,8Z,11Z,14Z-eicosatetraenoic-5,6,8,9,11,12,14,15-d8 acid); anandamide (AEA or N-
(2- hydroxyethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide); AEA-d4 (N-(2- hydroxyethyl-
1,1,2,2-d4)- 5Z,8Z,11Z,14Z-eicosatetraenamide); 2-arachidonoyl glycerol (2-AG or 
5Z,8Z,11Z,14Z-eicosatetraenoic acid, 2-glyceryl ester); 2-AG-d5 (5Z,8Z,11Z,14Z-
eicosatetraenoic acid, 2-glyceryl-1,1,2,3,3-d5 ester); N-arachidonoyl glycine (A-GLY or 
N-[1-oxo-5Z,8Z,11Z,14Z-eicosatetraenyl]-glycine); N-arachidonoyl-L-Serine (A-SER or 
N-[1-oxo-5Z,8Z,11Z,14Z-eicosatetraenyl]-L-serine); linoleoyl ethanolamide (LEA or N-
(2- hydroxyethyl)-9Z,12Z-octadecadienamide); LEA-d4 (N-(2-hydroxyethyl-1,1,2,2-d4)-
9Z,12Z-octadecadienamide); N-arachidonoyl dopamide (NADA or N-(2,3-(4-
dihydroxyphenyl)ethyl- 5Z,8Z,11Z,14Z-eicosatetraenamide); noladin ether (NE or 
5Z,8Z,11Z,14Z-eicosatetraen-2-glyceryl ether); oleoyl ethanlonamide (OEA or N-(2-
hydroxyethyl)-9Z-octadecenamide); OEA-d4 (N-(2-hydroxyethyl-1,1,2,2-d4)-9Z-
octadecenamide); palmitoylethanolamide (PEA or N-(2-hydroxyethyl)-
hexadecanamide); PEA-d5 (N-(2-hydroxyethyl)-hexadecanamide-15,15,16,16,16-d5); 
prostaglandin E2 (PRE2 or 9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic acid); 
PGE2-d4 (9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic-3,3,4,4-d4 acid); 
prostaglandin E2 ethanolamide (PGE2EA or N-(2-hydroxyethyl)-9-oxo-11α,15S-
dihydroxy-prosta-5Z,13E-dien-1-amide); stearoyl ethanolamide (SEA or N-(2-
hydroxyethyl)-octadecanamide); thromboxane B2 (THB B2 or 9α,11,15S-
trihydroxythromba-5Z,13E-dien-1-oic acid); virodhamine (VIR or O-(2-aminoethyl)-
5Z,8Z,11Z,14Z-eicosatetraenoic acid, ester, monohydrochloride)); from Sigma-Aldrich, 
Steinheim, Germany (aldosterone (ALDO or 11β,21-dihydroxypregn-4-ene-3,18,20-
trione); androsterone (ANDRO or 3α-hydroxy-5α-androstan-17-one); hydrocortisol or 
 cortisol (COR or 11β,17α,21-trihydroxypregn-4-ene-3,20-dione); trans-
dehydroepiandrosterone (DHEA or 3-β-hydroxy-5-androsten-17-one); ganaxolone 
(GANA or 3α-hydroxy-3β-methyl-5α-pregnan-20-one); progesterone (PROG or 4-
pregnene-3,20-dione); PROG-d9 (progesterone-2,2,4,6,6,17α,21,21,21-d9); 
tetrahydrodeoxycorticosterone (THDOC or 3α,21-dihydroxy-5α-pregnan-20-one) and 
allopregnanolone (THP or 5α-pregnan-3α-ol-20-one)), from Fluka (testosterone (TEST 
or 17β-hydroxy-4-androsten-3-one)); from Alsachim, Illkirch Graffenstaden, France 
(COR-d4 and  TEST-d4); and from TOCRIS (N-arachidonyl-gamma-aminobutyric acid 
(A-GABA or 4-[[(5Z,8Z,11Z,14Z)-1-Oxo-5,8,11,14-eicosatetraenyl]amino]butanoic 
acid)). HPLC-grade methanol (CH3OH), HPLC-grade acetonitrile (ACN), ammonium 
acetate, formic acid and phenylmethylsulfonyl fluoride (PMSF) were obtained from 
Sigma-Aldrich, Steinheim, Germany. HPLC-grade ethyl acetate was obtained from 
Acros Organics, New Jersey, USA. Absolute ethanol (EtOH) was obtained from the 
Federal Swiss Government. Deionized water (18.2 MΩ x cm) was obtained from an 
ELGA Purelab Ultra Genetic system (VWS (UK) Ltd, ELGA LabWater, UK). AQUASIL 
used for silanization was purchased from Thermo Scientific. 
 
2.2. Silanization of glass and plastic ware 
To prevent absorption of lipids, glass tubes and plastic tips were immersed for 2-5 min 
on AQUASIL solution (20 mL in 1L of distilled water), rinsed with methanol and dried at 
room temperature prior to the analysis.  
 
2.3. Standard solutions 
In order to prepare the standard mixtures used as calibrators (calibration solutions) and 
internal standards (IS), solutions of 1.0 and 0.01 mg/mL of analytical and labeled 
standards were prepared in EtOH. These solutions were kept at -80°C and the stability 
of the analytes was monitored throughout the analysis. The concentrations used for 
preparing calibrators and IS mixtures were selected according to the expected 
concentration of analytes in the plasma as well as their analytical limit of detection 
(LOD). Calibrators were divided in four concentration groups: The first group included 
AEA, LEA, NADA, PROG, TEST and VIR, in a calibration range from 0.04-50 ng/mL. 
 The second group contained 2-AG, A-GABA, A-GLY, ALDO, A-SER, NE, OEA, PEA, 
PGE2, SEA and THB B2 in a calibration range from 0.08-100 ng/mL. The third group 
included ANDRO, COR, DHEA, PGE2EA, THDOC and THP in an analytical range from 
0.4-500 ng/mL. The fourth group contained AA in an analytical range from 12.3-15000 
ng/mL. The concentrations of the labeled standards and GANA used as internal 
standards were: 20 ng/mL for AEA-d4, LEA-d4, OEA-d4, PEA-d5, PGE2-d4, PROG-d9 
and TEST-d4; 50 ng/mL for 2-AG-d5; 150 ng/mL for COR-d4; 400 ng/mL for GANA; and 
1500 ng/mL for AA-d8. In order to achieve these analytical concentrations in a final 
volume of 100 µL, 10 µL of a tenfold concentration of the calibrator and IS mixture were 
used (10 µL of 2-AG-d5 500 ng/mL solution, brought upto a final volume of 100 µL to 
achieve a concentration of 50 ng/mL). The calibration curve used for the analysis of 
plasma samples was built to include 6-9 calibration points.  
 
2.4. Plasma samples  
For the validation, pooled plasma purchased from the blood bank in Bern 
(Blutspendezentrum SRK Bern) was used. Aliquots of 0.5 mL were used to construct 
calibration curves and prepare quality control samples (QC). QC (n=6) were prepared to 
evaluate intra- and inter-day levels of precision (non-spiked samples (QC0)), and to 
evaluate the efficiency of analyte recoveries at low (QC4: level 4) and high (QC7: level 7) 
concentrations (see Table 4)). QC were prepared and stored at -80°C until analysis. QC 
used for the analysis of inter-day precision, recovery and stability were run over 4 
different days by two different analysts within a period of 4 weeks. The plasma used for 
preparing QC for intra-day analysis came from a different pool from the plasma used for 
preparing QC used for the inter-day evaluation. QC samples were prepared as follows: 
1) Frozen plasma was thawed for the analysis of intra-day variability (1 freeze/thaw 
cycle). 2) Plasma was thawed/aliquoted to prepare QC for the inter-day analysis (QC0, 
QC4 and QC7) and then frozen/thawed for the measurement of QC0, QC4 and QC7 for 
the inter-day analysis (2 freeze/thaw cycles).     
The quantities of arachidonic acid, prostanoids, ECs, EC-related lipids and steroids 
were measured in the plasma of 32 healthy male volunteers as part of a study 
performed at the Department of Psychiatry, Psychotherapy and Psychosomatics, 
 Psychiatric Hospital of the University of Zurich. The study was approved by the Ethics 
Committee of the Canton Zurich and all participants gave written informed consent 
before inclusion in the study. Blood was collected in 10 mL BD Vacutainer K2EDTA 
tubes for plasma (Vacutainer Systems, becton Dickinson, Plymouth, UK) and spiked 
with 10 µL of PMSF solution in ethanol into 1 mL of blood (final 1 mmol/L PMSF to 
protect against enzymatic activity by serine proteases). Plasma was obtained ca. 3 
hours after blood collection by centrifuging at 1,300 g for 10 min at 4°C. Blood samples 
were kept on ice until plasma generation. Plasma (ca. 5mL) was stored at -80°C prior 
the analysis.  
 
2.5. Sample preparation 
Plasma was thawed inside the refrigerator at 6°C for 3-4 hours prior the analysis (under 
our working conditions, 3 hours is the minimal time required for total thawing). In a 2 mL 
Eppendorf tube containing 1 mL ACN with 0.1 % formic acid, 10 µL of IS solution (see 
section 2.3, preparation of standard solutions) was spiked. The solution was kept at -
20°C for 30-60 min prior to processing. Using silanized pipette tips, 0.5 mL plasma was 
added to the spiked ACN solution. The mixture was thoroughly vortexed and placed 
inside the refrigerator (6°C) for 10 min to facilitate the protein precipitation process. 
Subsequently, the sample was centrifuged at 16,100 g at 4°C for 5 min. The 
supernatant was transferred to a silanized glass tube, diluted with 9 mL water and 
extracted by solid-phase separation (C18 Sep-Pak cartridge fromWaters AG Baden-
Dättwil, Switzerland, pre-activated with 3 mL CH3OH and equilibrated with 3 mL 10% 
ACN). Cartridges were washed with 3 mL 10% ACN and eluted with 3 mL ACN/ethyl 
acetate (1:1). The eluates were evaporated to dryness under nitrogen. The samples 
were reconstituted in 100 µL ACN (final volume) and centrifuged for 5 min at 16,100 g at 
4°C. Carefully, 80 µL were pipetted out, placed into conic amber vials and analyzed by 
LC-MS/MS (10 µL injection volume).    
 
2.6. Chromatographic and mass spectrometric conditions 
 
2.6.1. Equipment 
 Analyses were conducted on an LC-MS/MS system consisting of an API 4000 QTrap 
mass spectrometer equipped with a TurboIonSpray probe (AB Sciex Concord, Ontario, 
Canada) connected to a Shimadzu UFLC (Shimadzu Corporation, Kyoto, Japan). Data 
acquisition and analyses were performed using Analyst software version 1.5 (AB Sciex 
Concord, Ontario, Canada).    
 
2.6.2. Chromatographic conditions 
Analytical LC separations were performed on a Reprosil-PUR C18 column (3 µm 
particle size; 2×50 mm, Dr. A. Maisch, High Performance LC-GMBH, Ammerbuch, 
Germany) with a flow rate of 0.35 mL/min and oven temperature of 40°C using a 
gradient of CH3OH containing 2 mM ammonium acetate (eluent B) and water containing 
2 mM ammonium acetate and 0.1% formic acid (eluent A). The gradient was as follows: 
15% eluent B for 0.5 min; 15-70% B from 0.5 - 3.5 min; 70-99% B from 3.5-8.0 min and 
held at 99% from 8.0-11.0. From 11.0-11.5 min, the column was re-equilibrated to 15% 
B and conditioned from 11.5-13 min at 15% B. The autosampler was cooled at 4°C. 
 
2.6.3. MS/MS detection 
The TurboIon Spray interface was operated in negative ionization mode for the analysis 
of AA, PGE2 and THB2 and in positive mode for the analysis of AEA, 2-AG, A-GABA, A-
GLY, ALDO, ANDRO, A-SER, COR, DHEA, LEA, NADA, NE, OEA, PEA, PGE2-EA, 
PROG, SEA, TEST, THDOC, THP and VIR. The parameters of the source using 
nitrogen as a curtain gas were as follows: capillary ion spray voltage +4500 V in positive 
and -4250 V in negative modes, respectively; temperature 600 °C; curtain gas 25 psi, 
GS1 50 psi and GS2 50 psi. The entrance potential and collision cell exit potentials 
were both set to 10 V. The analytes were measured in the multiple reaction monitoring 
mode (MRM). Two MRM, one quantifier (Q) and one qualifier (q) were considered in the 
analysis. The MRM parameters (retention time, precursor ion/ product ion, declustering 
potential, collision energy) for the quantifier MRM used in the survey and the respective 
internal standard (IS) are presented in Table 1. For the negative ionization mode, a 
dwell time of 50 ms was used for all MRM transitions, while for the positive ionization 
mode, the schedule MRM function was applied (target scan time of 0.8 sec and MRM 
 detection window of 100 sec). Data were acquired and processed using Analyst 
software.  
 
2.7. Validation 
The method was validated using external calibrations spiking calibration solutions (see 
section 2.3) into plasma and processing following section 2.5 on 6 consecutive days 
(n=6). Quality control samples (n=6 of QC0, QC4 and QC7) were measured to fully 
validate the method (see section 2.4). The results were analyzed based on the peak 
area ratio between the analyte and IS. The IS used for each analyte measured are 
listed in Table 1. The full validation of the method was performed only for the analytes 
that could be detected in human plasma (AA, PGE2, THB B2, AEA, 2-AG, LEA, NE, 
OEA, PEA, SEA, ALDO, COR, DHEA, PROG and TEST). However, MRM, 
chromatographic conditions, LOD and low limit of quantification (LLOQ) of the analytes 
evaluated (except for VIR, which could not be recovered after spiking) were determined 
and are presented in Tables 1 and 2. Calibration curves were generated by subtracting 
the endogenous amount of an analyte from the spiked amount (blank subtraction). The 
results of the analysis allowed the determination of LOD, LLOQ, accuracy, linearity, 
precision and stability. The effect of the matrix on the analytes will be also discussed. 
Additionally, the levels of the compounds investigated were analyzed in 32 healthy male 
volunteers (see section 2.4).   
 
3. Results 
 
3.1. LOD/LLOQ  
Due to the endogenous presence of the validated analytes in plasma, the instrumental 
LOD (signal-to-noise ratio 3) of standards was used (Table 2). The LLOQ was obtained 
from spiked plasma as the concentration at which the signal-to-noise ratio was 10 and 
showed positive values after blank subtraction (the area ratio of a spiked analyte in 
plasma subtracting the area ratio of the analyte in blank plasma). For the analytes not 
detected in plasma, the LOD and LLOQ (Table 2) were determined as explained above 
 for the LLOQ of the endogenous substances (signal-to-noise ratio 3/10 for the 
LOD/LLOQ).   
 
3.2. Accuracy and linearity 
The accuracy (percentage ratio of the measured concentration and theoretical 
concentration) was determined at three concentrations (see Table 3). Samples were 
prepared by spiking the different calibration solutions together with the IS prior the 
addition of plasma (in a similar way as was used for the preparation of the calibration 
curves) and subsequent processing as described in section 2.5. After subtraction of the 
blank, the accuracy was determined. Quantification was performed using linear 
regression from calibration curves (ratio of peak area analyte/ peak area IS vs. analyte 
concentration) using 6-9 calibration points (see section 2.3). For all the analytes 
validated, the concentration range displayed directly proportional results (n=3) indicating 
that the method is linear. In Table 3, the results of accuracy and linearity are 
summarized.  
 
3.3. Precision, stability and recovery 
The precision (standard deviation) of the method was determined using quality control 
samples QC (see section 2.4) and the results are summarized in Table 4. The low intra-
day variability reflects the high performance of the method. All analytes show variation 
coefficients (CV) below 15%, except for AEA (20%). The inter-day analyses performed 
at three different concentrations (QC0, QC4 and QC7 (see section 2.4)) not only helped 
to establish the precision of the method, but also the stability (within 1 month). The 
highest variability is observed in QC4. This could be explained by the fact that the 
amounts of analytes spiked are low as compared to the endogenous levels of the 
analytes (the variability is less noticeable when spiking samples with higher 
concentrations of analytes, such as QC7). This can be better appreciated when 
comparing the concentration spiked in QC4 (Table 4) with the values reported in Table 5 
(i.e., dynamic range and average of the analytical concentration obtained from the 
analysis of 32 plasma samples from healthy male volunteers (see section 2.4). 
Considering the complexity of the plasma as a matrix, the results obtained for precision 
 are acceptable (see Table 4) and show that the samples are stable under the 
experimental conditions used here. The recovery, calculated at two concentrations (QC4 
and QC7), is within a conventional range of 70-130% (see Table 4). Recoveries were 
calculated after subtraction of blanks (average values of QC0) of spiked QC samples 
(average values of QC4 and QC7). Interestingly, a significant difference existed between 
the average values of intra-day and inter-day analyses for 2-AG and TEST (see Table 
4). As explained in section 2.3 (plasma samples), two different pool of plasma were 
used for the respective analyses.  
 
3.4. Matrix effect 
The assessment of the combined effect of the sample matrix and variable recoveries 
can be determined when evaluating the variability of the slopes (Table 3). Low variability 
(CV %) indicates that the precision and accuracy of the method are not affected by the 
matrix or by the workup. Additionally, to evaluate the matrix effect, absolute area values 
from calibration curves were used. Data obtained from calibrators spiked into solvent 
and processed (without matrix) and calibrators spiked in plasma (with matrix) were 
evaluated. We selected two subsequent arbitrary points inside the calibration curve and 
subtracted the area values to calculate a delta area. In theory, the delta area should be 
similar if a matrix effect does not exist. This is the case for most of the analytes (ALDO, 
COR, DHEA, OEA, PEA, PROG and TEST). However, the delta area is lower for AA, 
NE, PGE2 and THB B2, and higher for AEA, 2-AG and LEA, from which we conclude 
that a matrix effect for these analytes exists.   
 
3.5. Application of the method 
The levels of AA, AEA, 2-AG, ALDO, COR, DHEA, LEA, NE, OEA, PEA, PGE2, PROG, 
SEA, TEST, and THB B2 in human plasma were analyzed in 32 healthy male volunteers 
(A-GABA, A-GLY, ANDRO , A-SER, NADA, PGE2EA, THP, and THDOC were not 
detected). Mean plasma concentrations are reported in Table 5 together with their 
respective mean analytical concentrations. Additionally, values previously described in 
literature are also reported.  
 
 4. Discussion 
In an earlier study, we reported the results of an analysis of AA, 2-AG, AEA, OEA, PEA 
and PGE2 in fetal bovine sera (FBS) using a quantitative GC-MS method [11]. The 
extraction procedure used for FBS analysis was the starting point for the current LC-
MS/MS method validation in human adult plasma. The Folch extraction (as used in GC-
MS analysis of FBS) followed by SPE clean up did not allow the efficient recovery of 
PEA and SEA in plasma samples of humans or rodents. Therefore, we precipitated 
plasma proteins using ACN or cold acetone, as previously reported [26,27,32]. 
However, the use of cold acetone led to lower recoveries of the steroids measured (data 
not shown). Consequently, we selected ACN precipitation, followed by SPE clean up, 
prior to LC-MS/MS analysis (see section 2.5). Interestingly, publications citing other 
methods of extraction for N-acylethanolamides including PEA (e.g., 
chloroform/methanol/Tris-HCl  50 mM pH 7.5 (2:1:1, v/v) [33], ethyl acetate/n-hexane 
(9:1 v/v) [34], toluene [35], or directly using SPE (Oasis HLB) and elution with ACN 
[16]), did not describe any problems in their analyses. We evaluated the Folch 
extraction method and experienced difficulties only during the quantitative extraction of 
PEA and SEA in plasma - not in FBS - using both GC-MS and LC-MS/MS (data not 
shown). The reason for this remains unclear, but we assume that strong plasma protein 
(e.g., albumin) binding may have contributed to these difficulties. 
Originally, it was our intention to measure all analytes in a single injection. However, 
under the experimental conditions used this was not possible. Although the positive 
mode was the most sensitive mode for most of the compounds, AA, PGE2 and THB B2 
could not be analyzed in this mode [24,36–38]. Only one publication measured AA in 
positive mode (using a Micromass Quatro Micro spectrometer from Waters) [39], but 
these results could not be reproduced using our instrument. Nevertheless, by 
performing two subsequent injections (first in negative and then in positive mode), 
inserting blank runs in between, we were able to quantitate all compounds.   
 
With respect to the chromatography (see Figure 2 and supplementary Figure 1), all the 
analytes appeared as single peaks except for 2-AG (and its isomer 1-AG), 2-AG-d5, 
THB B2, and DHEA, which showed two peaks. In these cases, the two peaks were 
 integrated together for their analysis. Figure 2 shows chromatograms of the compounds 
validated with the presented method (standards and plasma).  
 
To assess the reliability of the method, we compared the values obtained from healthy 
male volunteers with similar results previously reported in literature (see Table 5). In 
some cases, it was not possible to find information about the levels of the analytes 
studied only in males and, therefore, levels for both males and females or only females 
are presented in Table 5. The results obtained for AA, AEA, 2-AG, COR, DHEA, PROG 
and TEST are in full agreement with values reported in the literature [24–27,40–44]. The 
plasma levels of PROG show a high level of fluctuation in females, which is dependent 
on the age and stage of reproductive cycle [31]. This fluctuation has also been reported 
for AEA [28] although it remains questionable whether small AEA variations are 
physiologically meaningful. COR is a stress marker in humans and, therefore, the levels 
in plasma are known to oscillate under conditions of stress like participating in an 
experiment.   
The values of OEA, PEA and SEA reported here are slightly higher than the values 
appearing in the literature. Both studies used for comparison only reported the gender, 
age and health status of the donors, but did not give information about the collection 
procedure or treatment of the samples prior to the analysis [26,27]. Most importantly, 
the use of PMSF blocks the enzymatic degradation of N-acylethanolamines by serine 
hydrolases, which may be reflected in the higher values obtained in the present study. 
In the case of LEA, no information could be found with regard to endogenous levels in 
human plasma, although we estimate that it is between 0.5-23 pmol/mL, according  to 
information stated elsewhere [45].  
NE was originally isolated from pig brain and described as an endocannabinoid in 2001 
[46]. Subsequently, it was reported only once more from rat brains and peripheral 
tissues [47]. NE has, however, never been reported in human plasma. In our study, we 
could detect NE in human plasma (data not shown). This finding requires further 
validation using high-resolution MS and additional experiments with blood samples from 
other mammals, which goes beyond the description of the method reported here. 
Interestingly, two sensitive methods have been validated for the measurement of NE in 
 human plasma, but neither of them reported endogenous levels [25,27]. The LLOQ 
reported for NE by [25] (0.3 ng/mL) was lower than the LLOQ reported here (3.2 
ng/mL). These studies used an API 4000 QTrap mass spectrometer in positive mode 
(as used here), but a different extraction procedure (single extraction with n-heptane/ 
ethyl acetate (1/1, v/v)), solvent composition for the LC (ACN and water both with 0.1% 
formic acid) and MRM transition (365/273). On the other hand, the method reported by 
Balvers et al. [27], which uses a similar sample preparation method (ACN for extraction 
followed by a cleanup using SPE), but a different mass spectrometer (Thermo Finnigan 
TSQ Quantum triple quadrupole), distinct solvent composition for the LC (methanol and 
water containing 13 mM ammonium acetate and 0.1% formic acid) and different MRM 
transitions (382 [M+NH4]+/91) shows a higher LLOQ (647 pg on column) as compared 
to ours (32 pg on column).  
The basal levels of PGE2 and THB B2 reported by Shinde et al. [24] are below our LOD. 
It is known that prostanoid levels can increase in response to inflammation and 
pathophysiological conditions [48]  and that the method can measure increased levels in 
plasma of PGE2 and THB B2. In 4 of the 32 samples analyzed, we observed THB B2 at 
the LOD. The ALDO levels reported here with our method are higher that the levels 
reported in the literature,  which compare radioimmunoassay (RIA) with LC-MS/MS 
(negative mode) [29,30]. Both literature sources showed good correlations between the 
two methods of analysis (higher variation with RIA), however, only one of them provided 
information about the sample collection (samples were collected at midmorning from 
normotensive patients [29]). The time at which the blood was collected and the 
condition of the subjects (fasting or not) are known to be critical in the analysis of 
steroids. The levels of aldosterone reported in the present study are in agreement with 
those reported by Hollenberg et al. [49], who used RIA for the analysis of plasma 
samples. In that study, the samples were collected in the morning under fasting 
conditions that are similar to those used in our study. 
    
Different studies have reported levels of THDOC and THP in human and rodent plasma 
using gas chromatography chemical ionization mass spectrometry (GC-MS) or 
radioimmunassays [50–55]. Using our LC-MS/MS, we were unable to detect these 
 analytes. In the case of THP, the LOD/LLOQ reported is the only reference to our 
knowledge that also includes analytical information about the method (ca. 1 pg/ 10 pg 
on column [50]) is lower that our LOD/ LLOQ (160/ 400 pg on column (see Table 2)). 
Accordingly, only very low levels of THP were reported for plasma (77+20 pg/mL or 
0.2+0.1 pmol/mL) in this study, leading us to question the physiological relevance of 
these amounts. With respect to the analysis of THDOC, most articles refer to Romeo et 
al. [56,57],  in which a full method description is missing. Nevertheless, our LOD for 
THDOC (2.5 ng on column) was much higher than the one reported for THP (see Table 
2). Furthermore, our method was not able to detect endogenous concentrations of A-
GABA, A-GLY, A-SER, ANDRO, PGE2EA and NADA in human blood plasma. In 
agreement with our findings, two studies have tried to measure NADA and A-GLY in 
human plasma without success [25,27]. So far, A-GABA and A-SER have only been 
identified in the mouse brain [58]. 
 
5. Conclusions 
In this study we validated an analytical method that enables researchers to 
simultaneously measure bioactive lipids from different metabolite networks. The present 
method is sensitive, accurate and precise. It allows the quantification of selected 
prostanoids, ECs, N-acylethanolamines and steroids in human plasma. This analytical 
LC-MS/MS method enables the analysis of co-variations of these metabolites in human 
plasma under pathophysiological conditions.    
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Table 1 
MRMs and chromatographic conditions for the analytes and IS evaluated in human 
plasma. 
 Analyte IS used Retention time (min) Q/q
Precursor ion 
(m/z )
Product ion 
(m/z )
Declustering 
potential (eV)
Collition 
energy (eV) Observation
Analytes measured in negative mode
AA AA-d 8 8.57 Q 303 59 -80 -37
q 303 205 -80 -18
PGE2 PGE2-d 4 5.37 Q 351 315 -70 -25
q 351 271 -70 -16
THB B2 PGE2-d 4 5.25/5.47 Q 369 195 -62 -20 double peak
q 369 169 -62 -23
Analytes measured in positive mode
AEA AEA-d 4 8.02 Q 348 62 56 42
q 348 133 56 33
2-AG 2-AG-d5 8.11/8.22 Q 379 203 82 25 double peak
q 379 287 51 18
A-GABA AEA-d 4 8.03 nd 390 86 68 45
nd 390 104 68 22
A-GLY AEA-d 4 7.93 nd 362 203 70 21
nd 362 269 70 18
ALDO COR-d 4 4.77 Q 361 109 80 48
q 361 97 80 52
ANDRO TEST-d 4 6.34 nd 291 135 76 30 fronting
nd 291 147 76 32
A-SER AEA-d 4 7.78 nd 392 106 63 22
nd 392 287 63 15
COR COR-d 4 4.89 Q 363 97 76 48 fronting
q 363 121 76 38
DHEA TEST-d 4 5.61/5.76 Q 289 253 72 15 double peak
q 289 213 72 26
LEA LEA-d 4 7.97 Q 324 62 74 36
q 324 109 74 32
NADA AEA-d 4 8.06 nd 440 137 75 34
nd 440 154 75 23
NE 1/2-AG-d5 8.42 Q 365 121 86 29 tailing
q 365 133 86 40
OEA OEA-d 4 8.38 Q 326 62 72 36
q 326 309 72 21
PEA PEA-d 5 8.21 Q 300 62 78 36
q 300 283 78 19
PGE2EA AEA-d 4 5.02 nd 396 62 35 49 fronting
nd 396 360 35 16
PROG PROG-d 9 6.25 Q 315 109 83 36
q 315 97 83 34
SEA PEA-d 5 8.81 Q 328 62 72 31
q 328 311 72 22
TEST TEST-d 4 5.61 Q 289 97 80 33
q 289 109 80 36
THDOC GANA 6.31 nd 335 135 80 30
nd 335 281 80 16
THP GANA 7.09 nd 319 301 70 13
nd 319 257 70 18
VIR* AEA-d 4 7.05 nd 348 62 62 41
nd 348 203 62 21
IS measured in negative mode
AA-d 8 8.53 IS 311 59 -90 -38
PGE2-d 4 5.36 IS 355 319 -64 -17
IS measured in positive mode
AEA-d 4 8.01 IS 352 66 60 35
2-AG-d5 8.09/8.20 IS 384 287 62 17 double peak
COR-d 4 4.88 IS 367 121 78 35
GANA 7.54 IS 333 297 76 18
LEA-d 4 7.96 IS 328 66 70 35
OEA-d 4 8.38 IS 330 66 72 32
PEA-d 5 8.21 IS 305 62 70 40
PROG-d 9 6.21 IS 324 100 83 37
TEST-d 4 5.6 IS 293 98 80 32
*VIR  could only been see the standards. Therefore, it was not further asseed.
nd: not determine
Q: MRM transition used as quantifier
q: MRM transition used as quanlifier
IS: internal standard
Table 2 
LODs and LLOQs of all MRM transitions of the analytes evaluated. 
 
 
  
Analyte Q/q Precursor ion (m/z )
Product 
ion (m/z )
LOD 
(ng/mL)
LOD (pg on 
column)
LOD (fmol on 
column)
LOQ 
(ng/mL)
LOQ (pg on 
column)
LOQ (fmol on 
column)
AA Q 303 59 12.3i 123.0 404.6 192 1920.0 6315.8
q 303 205 12.3i 123.0 404.6 192 1920.0 6315.8
AEA Q 348 62 0.04i 0.4 1.2 0.1 1.0 2.9
q 348 133 0.1i 1.0 2.9 0.6 6.4 18.4
2-AG Q 379 203 0.6i 6.0 15.9 3.2 32.0 84.7
q 379 287 0.3i 3.0 7.9 3.2 32.0 84.7
A-GABA nd 390 86 0.2 2.0 5.1 <0.5 5.0 12.9
nd 390 104 0.2 2.0 5.1 <0.5 5.0 12.9
A-GLY nd 362 203 3.2 32.0 88.6 8 80.0 221.6
nd 362 269 3.2 32.0 88.6 8 80.0 221.6
ALDO Q 361 109 0.5i 5.0 13.9 3.2 32.0 88.9
q 361 97 0.5i 5.0 13.9 3.2 32.0 110.3
ANDRO nd 291 135 40 400.0 1379.3 100 1000.0 3448.3
nd 291 147 100 1000.0 3448.3 250 2500.0 8620.7
A-SER nd 392 106 3.2 32.0 81.8 8 80.0 204.6
nd 392 287 3.2 32.0 81.8 8 80.0 204.6
COR Q 363 97 0.4i 4.0 11.0 6.4 64.0 176.8
q 363 121 0.4i 4.0 11.0 6.4 64.0 176.8
DHEA Q 289 253 2.6i 25.6 88.9 2.6 25.6 88.9
q 289 213 2.6i 25.6 88.9 2.6 25.6 88.9
LEA Q 324 62 0.04i 0.4 1.2 0.1 1.0 3.1
q 324 109 0.6i 6.0 18.6 1.6 16.0 49.5
NADA nd 440 137 4 40.0 91.1 10 100.0 227.8
nd 440 154 4 40.0 91.1 10 100.0 227.8
NE Q 365 121 1.3i 12.8 35.2 3.2 32.0 87.9
q 365 133 3.2i 32.0 87.9 3.2 32.0 87.9
OEA Q 326 62 0.08i 0.8 2.5 0.51 5.1 15.7
q 326 309 0.2i 2.0 6.2 1.28 12.8 39.4
PEA Q 300 62 0.08i 0.8 2.7 3.2 32.0 107.0
q 300 283 0.51i 5.1 17.1 8 80.0 267.6
PGE2 Q 351 315 0.2
i
2.0 5.7 0.51
i
5.1 14.5
q 351 271 0.2i 2.0 5.7 0.51i 5.1 14.5
PGE2EA nd 396 62 32 320.0 810.1 80 800.0 2025.3
nd 396 360 200 2000.0 5063.3 500 5000.0 12658.2
PROG Q 315 109 0.04i 0.4 1.3 0.1 1.0 3.2
q 315 97 0.04i 0.4 1.3 0.1 1.0 3.2
SEA Q 328 62 0.08i 0.8 2.4 8 80.0 244.6
q 328 311 0.51i 5.1 15.6 8 80.0 244.6
TEST Q 289 97 0.04i 0.4 1.4 0.1 1.0 3.5
q 289 109 0.04i 0.4 1.4 0.1 1.0 3.5
THDOC nd 335 135 250 2500.0 7485.0 500 5000.0 14970.1
nd 335 281 250 2500.0 7485.0 500 5000.0 14970.1
THP nd 319 301 16i 160.0 503.1 40i 400.0 1257.9
nd 319 257 16i 160.0 503.1 40i 400.0 1257.9
THB B2 Q 369 195 0.51 5.1 13.8 3.2 32.0 86.5
q 369 169 0.51 5.1 13.8 3.2 32.0 86.5
i Intrumental limit of detection
Table 3 
Dynamic range, linearity and accuracy of the MRM transitions selected for the 
quantification of ECs, N-acylethanolamines, prostanoids and steroids found in human 
plasma. 
 
  
Analyte Precursor ion (m/z )
Product 
ion (m/z )
Dynamic range 
mesured (ng/mL) R
2(+SD, n=3) Slope Intercept 
Amount spiked 
(ng/mL) (%, n=6)
AA 303 59 192-15000 0.998+0.002 0.0007+0.00003 0.8846+0.7670 3000 136+24
7500 130+13
15000 115+8
AEA 348 62 0.1-50 0.993+0.006 0.0596+0.0035 0.0131+0.0469 1.6 132+48
4 110+21
10 113+14
2-AG 379 203 1.28-100 0.984+0.016 0.0108+0.0010 .-0.024+0.065 20 70+49
50 106+20
100 105+20
ALDO 361 109 3.2-100 0.999+0.001 0.0019+0.0001 0.0015+0.0011 3.2 111+43
8 113+20
20 103+13
COR 363 97 6.4-1000 0.996+0.002 0.0015+0.00003 0.0182+0.0168 250 113+10
500 106+9
1000 106+4
DHEA 289 253 2.6-500 0.994+0.005 0.0003+0.00001 0.0033+0.0014 40 88+52
100 83+51
250 79+49
LEA 324 62 0.1-50 0.992+0.005 0.0160+0.0004 0.0136+0.0045 4 121+15
10 108+8
25 114+11
NE 365 121 3.2-100 0.991+0.012 0.0122+0.0005 0.0212+0.0106 3.2 114+35
8 105+25
20 112+17
OEA 326 62 0.51-100 0.998+0.002 0.0735+0.0053 .-0.0034+0.0232 8 103+18
20 103+9
50 104+8
PEA 300 62 3.2-100 0.995+0.003 0.0080+0.0005 0.0060+0.0077 8 96+24
20 100+13
50 105+16
PGE2 351 315 3.2-100 0.993+0.009 0.0369+0.0049 0.0704+0.1172 20 103+22
50 102+17
100 96+16
PROG 315 109 0.1-50 0.999+0.001 0.0868+0.0039 0.0264+0.0056 0.64 114+16
1.6 108+11
4 108+14
SEA 328 62 8-100 0.995+0.004 0.0070+0.0011 0.0073+0.0113 8 91+25
20 102+29
50 93+21
TEST 289 97 0.1-50 0.999+0.001 0.0818+0.0052 0.0245+0.0068 10 102+9
25 101+9
50 97+8
THB B2 369 195 0.51-100 0.998+0.003 0.0437+0.0035 0.0236+0.0102 1.28 105+20
8 130+18
20 102+14
Q Accuracy plasma
Table 4  
Analysis of quality control samples (QC): Intra- and inter-day precision and recovery analyses. 
  
  
Analyte Precursor ion (m/z )
Product ion 
(m/z )
Calculated 
conc. 
(pmol/mL)
CV (%)
Calculated 
conc. 
(pmol/mL)
CV (%)
AA 303 59 5524.3+198.8 3.9 4882.8+755.7 15.5 192 116 19.3 3000 129 16.2
AEA 348 62 1.4+0.3 19.6 1.4+0.2 16.1 0.64 88 25.8 10 128 11.1
2-AG 379 203 42.8+2.8 6.1 72.2+9.8 13.6 1.28 a 16.2 20 118 15.1
ALDO 361 109 5.4+0.3 5.0 3.4+1.0 29.3 1.28 96 4.6 20 128 8.3
COR 363 97 126.6+4.7 3.5 117.0+9.9 8.4 6.4 98 10.9 100 134 10.3
DHEA 289 253 13.2+1.8 10.4 15.8+4.1 25.7 6.4 104 24.1 100 115 9.5
LEA 324 62 3.3+0.4 10.6 3.9+0.4 9.3 0.64 95 14.0 10 120 9.4
NE 365 121 5.6+0.5 8.5 10.1+3.8 37.5 1.28 73 41.2 20 108 23.9
OEA 326 62 7.6+0.3 4.5 7.1+0.8 11.3 1.28 113 6.9 20 127 15.1
PEA 300 62 19.6+1.6 8.2 22.3+3.9 17.7 1.28 a 20.5 20 109 16.3
PGE2 351 315 * * * * 1.28 * * 20 * 13.3
PROG 315 109 0.6+0.05 3.3 0.5+0.1 12.5 0.64 134 9.2 10 129 11.5
SEA 328 62 15.9+1.1 11.2 19.8+5.1 26.0 1.28 104 18.3 20 104 22.0
TEST 289 97 4.3+0.2 3.5 8.5+0.8 9.4 0.64 79 7.5 10 119 12.3
THB B2 369 195 0.3+0.1 15.1 <lod - 1.28 77 44.0 20 94 13.3
* Peaks coming at the same retention time (signal overlapping) 
a Not possible to obatain the recovery (amount spiked was too little)
CV (%)
QC0 (n=6) QC4 (n=6) Inter-day QC7 (n=6) Inter-day
Intra-day Inter-day
Amount 
spiked (ng/mL) Recovery (%) CV (%)
Amount 
spiked (ng/mL) Recovery (%)
Table 5  
Dynamic range, linearity and accuracy of the MRM transitions selected for the quantification of ECs, N-acylethanolamines, prostanoids 
and steroids found in human plasma. 
Analyte Precursor ion (m/z )
Product ion 
(m/z )
Analytical dinamic 
range (ng/mL)
Analytical amount found in 
plasma; n=32 (ng/mL) 
Concentration found in plasma of healthy 
subjects; n=32 (pmol/mL)
Plasma concentration reported in literature values from 
healthly subjects (pmol/mL)
AA 303 59 192-15000 6063+2692 5063+2606 3759.9+1539.5 (n=6, M) [24]
AEA 348 62 0.1-50 2.6+0.7 1.7+0.4 0.1-4.6 ** [40]; 0.3-1.5 (n=5, MF) [25]; 0.7+0.02 (n=ns, M) [26]; 
0.7+0.3 (n=23, F) [27]; 0.72+0.22 (n= ns, ns) [28]
2-AG 379 203 1.28-100 31.2+10.0 16.5+5.3 0.6-18.7** [40]; 5.7-10.6 (n=5, MF) [25]; 18.8+32.8 (n=ns, M) [26]; 
18.8+32.8 (n=23,F) [27]
ALDO 361 109 3.2-100 14.8+2.6 8.2+1.4 7.2+0.7 (n=58, MF, RIA) [49]; <0.1-0.6 (n=97, MF) [29]; 0.1-1.0 
COR 363 97 6.4-1000 640+184 354+102 100-790 (n=9, MF) [10]; 101.2-713.6 (2.5-97.5% of n=66, M (>16 
years old)) [31]
DHEA 289 253 2.56-500 46.9+11.0 32.6+7.6 5-45 (n=12, M; GCMS) [42]
LEA 324 62 0.1-50 6.7+1.9 4.1+1.2 nr
OEA 326 62 0.51-100 16.0+4.0 9.9+2.4 4.9+0.4 (n=ns ,M) [26]; 4.2+1.3  (n=23, F) [27]
PEA 300 62 3.2-100 34.4+7.7 23.0+5.2 5.2+0.5 (n=ns ,M) [26]; 4.6+1.2  (n=23, F) [27]
PGE2 351 315 3.2-100 <lod - 0.08+0.04 (n=6, M) [24]
PROG 315 109 0.1-50 0.5+0.2 0.3+0.1 0.32-42.45 (n=20 F, full cycle CIA) [43]; 4-65 (n=22, MF, GCMS) 
[44]; 0.1-0.7 (2.5-97.5% of n=66, M (>16 years old) [31]
SEA 328 62 8-100 21.5+9.7 13.1+5.9 1.6+0.6 (n=23, F) [27]
TEST 289 97 0.1-50 19.7+4.8 13.7+3.4 8-90 (n=12 M; GCMS) [42]
THB B2 369 195 0.51-100 0.1+0.1** 0.4+0.4** 0.48+0.18 (n=6, M) [24]
M= male; F= female; MF= male and female; pmF=postmenopausal women 
*Only a few samples contain THB B2 slightly above the LOD
**n=4; <LOQ
ns= not specified
CIA= chemiluminescent immunoassay
RIA= radioimmunoassay
GCMS= gas chromatography mass spectromety
nr= not reported
Supplementary Table 1 
Instrumental LOD of the MRM transitions of the analytes that were not found in human plasma in this study. 
 
Analyte Precursor ion (m/z )
Product 
ion (m/z )
LOD 
(ng/mL)
LOD (pg on 
column)
LOD (fmol on 
column)
A-GABA 390 86 0.08 0.8 2.1
390 104 0.08 0.8 2.1
A-GLY 362 203 3.2 32.0 88.6
362 269 3.2 32.0 88.6
ANDRO 291 135 6.4 64.0 220.7
291 147 6.4 64.0 220.7
A-SER 392 106 1.28 12.8 32.7
392 287 1.28 12.8 32.7
NADA 440 137 1.28 12.8 29.2
440 154 1.28 12.8 29.2
PGE2EA 396 62 20 200.0 506.3
396 360 20 200.0 506.3
THDOC 335 135 40 400.0 1197.6
335 281 40 400.0 1197.6
THP 319 301 16 64.0 201.3
319 257 16 64.0 201.3
VIR 348 62 3.2 32.0 86.5
348 203 8 80.0 216.2
Fig. 1. Chemical structures of the analytes measured in human plasma with LC-
MS/MS. A: Endocannabinoids, N-acylethanolamines, prostanoids. B: Steroids  
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Fig. 2. Chromatograms of the analytes measured in positive mode. A: Chromatogram 
showing MRM transitions of analytes and internal standards (IS) of “only standards”. 
B and C: Chromatograms of individual analytes. First row: analytes of “only 
standards”, second row: IS of “only standards”, third row: endogenous levels of 
analytes (one representative example of n=32) found in plasma and fourth row: IS in 
plasma. 
 
  
  
Figure 3: Chromatograms of the analytes validated with the presented method run 
in positive mode. A: Chromatogram showing MRM transitions of analytes and internal 
standards (IS) of “only standards”. B: Individual chromatograms of analytes. First 
raw: analytes of “only standards”, second raw: IS of “only standards”, third raw: 
endogenous levels of analytes (e.g. one of n=32) find “in plasma” and fourth raw: IS 
recovered from analysis “in plasma”.   
Supplementary Figure 1: Chemical structures of the analytes investigated that were 
not detected in human plasma (Not validated). A: Endocannabinoid-like lipids, B: 
Steroids 
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Supplementary Figure 2: Chromatograms of the analytes investigated that were not 
detected in human plasma. The top panel shows a chromatogram of all the analytes 
investigated. The bottom panel shows individual chromatograms of the two MRM 
transitions of the analytes that were not detected in human plasma and not further 
validated.   
 
